Editorial: Targeting the Interleukin-1β/Interleukin-6/C-reactive Protein Pathway in Clinical Medicine -A Road Map to Clinical Trial Design

Jan Torzewski^1*Ahmed Sheriff²Janos G Filep³Karlheinz Peter⁴Paul Ridker⁵

• ¹Kempten Clinic, Kempten, Germany
• ²Charite - Universitatsmedizin Berlin, Berlin, Germany
• ³Universite de Montreal, Montreal, Canada
• ⁴Baker Heart and Diabetes Institute Central Australia, Alice Springs, Australia
• ⁵Harvard Medical School, Boston, United States

monomeric CRP (mCRP), may be a better and even more specific marker of intraocular inflammatory conditions in particular and of inflammation in general. In this context, a beautiful review article by Abisjhek Roy and colleagues on the role of CRP as a potential nexus between inflammation and protein misfolding diseases may well be regarded as the highlight of this Research Topic (https://doi.org/10.3389/fimmu.2025.1612703). The review article further explores the impact of the complex interplay between CRP and its isoforms pCRP, pCRP*, and mCRP in protein misfolding diseases, with a focus on neurodegenerative disease pathogenesis.Inhibition of IL-1 and IL-6 by specific antibodies has gone far down the line in clinical medicine (1-2). Concerning chronic application, which is needed for the primary or secondary prevention of cardiovascular disease, costs and infectious complications may present limitations (2). Whereas IL-1 antibodies have been proven to lower cardiovascular events in the absence of any change in cholesterol (3), these agents have been repurposed into oncology given even larger benefits on lung cancer (4). Nonetheless, there is great hope and interest in effects downstream of IL-1 and on IL-6 itself (1-2, 5). Due to the pivotal role of IL-6 in the humane immune system, careful consideration of potential off-target effects caused by chronic IL-6 inhibition is required. The latter issues are currently being investigated in a series of randomized controlled trials (RCTs) which will have a significant impact on our understanding of the role of IL-1β/IL-6/CRP pathway in clinical medicine (1)(2)(3)(4)(5). Interestingly, low dose colchicine has recently achieved FDA approval for the prevention of cardiovascular disease and a class IIA recommendation in the American and European Guidelines (6-7). Colchicine, in addition to tubulin disruption being the primary mechanism of action, may indirectly inhibit NACHT-LRRPYD-containing 3 (NALP3) inflammasomes and IL-1β processing and release (6)(7). This may in part explain its effects on cardiovascular disease prevention and CRP levels (7). In contrast to the use of colchicine for chronic stable atherosclerosis, there is controversy related to colchicine in the setting of acute coronary ischemia where trial data to date have been neutral (8) suggesting that "timing the taming of inflammation" may have clinical relevance (9). Gastrointestinal side effects of colchicine and the higher incidence of death from non-cardiovascular causes in the original LoDoCo2 trial (5) remain a matter of concern.Finally, specific CRP inhibition has become a matter of investigation. Despite huge pharmacological efforts, attempts to specifically inhibit hepatic CRP synthesis have largely failed to reach human application (10). Promising results, mainly in the setting of acute myocardial infarction (AMI), have been achieved with CRP apheresis (11)(12). The scientific community avidly awaits data from the Innsbruck trial re-evaluating the effect of CRP apheresis on the reduction of myocardial infarction size in a randomized controlled setting (https://ichgcp.net/de/clinical-trials-registry; NCT04939805). Depending on the o u t c o m e of this trial, a further RCT investigating the effect of CRP apheresis on sound clinical endpoints in AMI is being planned (13) and thereby increasing their specificity may become a crucial pharmacological path (14)(15).In summary, this Research Topic may contribute to the understanding of future avenues towards the success of targeting the IL-1β/IL-6/CRP pathway in clinical medicine.